Balthaser Kevin 4

What Happened
Kevin Balthaser, Chief Financial Officer of Aclaris Therapeutics (ACRS), had restricted stock units (RSUs) convert into 14,750 shares on Feb 1, 2026. To satisfy tax withholding obligations related to the vesting/settlement, the issuer withheld 4,984 of those shares at $3.51 per share, yielding approximately $17,494. This was a settlement of an award, not an open-market sale or purchase.

Key Details

• Transaction date: 2026-02-01; Form 4 filed 2026-02-03.
• Conversion/settlement: 14,750 shares acquired via conversion of RSUs (derivative code M).
• Tax withholding: 4,984 shares withheld (code F) at $3.51/share for ~$17,494.
• Reported disposition of derivative: an entry shows 14,750 shares with $0 per share (derivative conversion/settlement).
• Shares owned after the transaction: not specified in the provided filing details.
• Footnotes:
  • F1: Each RSU represents a contingent right to one share.
  • F2: Withholding of shares by the issuer to satisfy tax withholding upon vesting/settlement.
  • F3: RSUs vest in four equal installments on the first through fourth anniversaries of Feb 1, 2024, subject to continuous service.

Context
This was a routine equity award settlement and a tax-withholding action (often called a cashless/stock withholding), not an open-market sale or purchase. Such withholding transactions are common when RSUs vest and do not necessarily indicate the insider’s view on the company’s stock.